Registration is now open. The meeting, which runs from April 12-14, takes place in Barcelona, Spain, with virtual attendance options for registrants who can’t make it in person. Applications for company presentations are open until December 14, 2022. Learn more!
Looking for updates on future ARM events? Sign up for our email list here!
The Alliance for Regenerative Medicine and the American Society for Cell and Gene Therapy released a report addressing potency-assay related development delays for cell and gene therapies, in response to an October 19 meeting with regulators and other concerned parties.
The Alliance for Regenerative Medicine (ARM) announced today the appointment of Rita Johnson-Greene as Chief Operating Officer, effective April 10.
The Alliance for Regenerative Medicine released its Workforce Report: Gap Analysis for the Cell and Gene Therapy Sector. This report provides a landscape overview and gap analysis of the workforce needed for sustainable biomanufacturing of cell and gene therapies in the United States.
ARM is seeking a Vice President, Government Affairs to lead the tactical execution of ARM’s mission and core Congressional and Agency components of our long-term strategic plan for the US.
Learn more and apply
View on LinkedIn
Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.
Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders.
ARM takes the lead on the most important issues facing the regenerative medicine and advanced therapy sector today:
As the global voice of the sector, we represent more than 475 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.